| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3820694 | La Presse Médicale | 2011 | 8 Pages |
Abstract
Additional molecules, with new targets, must be developed in the future to take care of 25% of the patients with an epilepsy resistant to adapted and well-conducted treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Vincent Navarro,